CD8A and neoplasm: It maintained a high ratio of CD8+ T lymphocytes in the spleen, peripheral blood, and tumor tissues, restored the cytotoxicity of tumor-infiltrating CD8+ T lymphocytes, and enhanced the antitumor effect when combined with the PD-1 inhibitor (49).